A meta‐analysis on the association of HER‐2 overexpression with prognosis in human osteosarcoma |
| |
| Authors: | Y.G. LI msc X. GENG msc |
| |
| Affiliation: | 1. Department of Laboratory, Cancer Hospital of Tianjin Medical University, Tianjin;2. Research center of Tianjin Medical University, Tianjin, China |
| |
| Abstract: | LI Y.G. & GENG X. (2010) European Journal of Cancer Care 19, 313–316
A meta‐analysis on the association of HER‐2 overexpression with prognosis in human osteosarcoma Various studies examining the relationship between HER‐2 overexpression and clinical outcome in patients with osteosarcoma have yielded inconclusive results. The purpose of the current study was to evaluate the relation of HER‐2 status with clinical outcome in osteosarcoma. We conducted a meta‐analysis of five studies that evaluated the relation between HER‐2 status and 2‐year survival. DerSimonian‐Laird random effects analysis was used to estimate the effects of HER‐2 overexpression on 2‐year survival. The combined relative risk in patients with osteosarcoma for 2‐year survival was 1.26 (95% confidence interval, 0.50–3.14; P = 0.63). HER‐2‐positive status tended to be associated with a worse 2‐year survival, but the overall results were not formally statistically significant. An unfavourable prognostic effect of HER‐2 overexpression in osteosarcoma was evident from the meta‐analysis. However, because several studies were excluded by the current eligibility criteria, caution is needed in interpreting the results. |
| |
| Keywords: | meta‐analysis osteosarcoma HER‐2 erbB2 neu survival |
|
|
